Gunew Marcus N, Menrath Victor H, Marshall Rhett D
The Cat Clinic Mt Gravatt, Mt Gravatt, QLD, Australia.
J Feline Med Surg. 2008 Jul;10(3):235-41. doi: 10.1016/j.jfms.2007.10.007. Epub 2008 Apr 28.
Osteoarthritis is a chronic, painful condition that is now recognised as affecting a large proportion of cats. Non-steroidal anti-inflammatory drugs (NSAIDs) have proven efficacy in dogs and humans but there are limited published data on the use of NSAIDs in the long-term management of this condition in cats. This prospective study aimed to assess the long-term safety and palatability of oral meloxicam and its efficacy in treating osteoarthritic pain in cats when given at a dose of 0.01-0.03 mg/kg once daily. Forty cats diagnosed with osteoarthritis completed the trial with a mean treatment duration of 5.8 months. Gastrointestinal upset in 2/46 (4%) cats was the only adverse effect noted. No deleterious effect on renal function was detected in cats studied. Owners subjectively assessed treatment efficacy as good or excellent in 34/40 (85%) of cases. The results of this study showed oral meloxicam to be safe and palatable long-term treatment for osteoarthritis in cats when given with food at a dose of 0.01-0.03 mg/kg.
骨关节炎是一种慢性疼痛疾病，目前已知有很大比例的猫受其影响。非甾体抗炎药（NSAIDs）已被证明对犬类和人类有效，但关于NSAIDs用于猫骨关节炎长期治疗的已发表数据有限。这项前瞻性研究旨在评估口服美洛昔康的长期安全性和适口性，以及在以0.01 - 0.03毫克/千克的剂量每日给药一次时治疗猫骨关节炎疼痛的疗效。40只被诊断患有骨关节炎的猫完成了试验，平均治疗持续时间为5.8个月。仅观察到2/46（4%）的猫出现胃肠道不适这一不良反应。在接受研究的猫中未检测到对肾功能的有害影响。在34/40（85%）的病例中，主人主观评估治疗效果为良好或极佳。这项研究的结果表明，当以0.01 - 0.03毫克/千克的剂量与食物一起给药时，口服美洛昔康是治疗猫骨关节炎的安全且适口的长期治疗方法。
